Homiez

In July 2026, Homiez concentrated 51.23% of sales in Pre-Roll with year-over-year growth of 168.68% and month-over-month expansion of 36.61%, while Concentrates captured 42.40% share with a sharper 530.22% YoY surge and a 56.31% MoM rise; Flower contracted to 6.02% share with 162.55% YoY growth but a -25.28% MoM decline. Average price fell 47.28% YoY to $10.49 as category pricing diverged, with Pre-Roll averaging 15.50 and Concentrates at 7.17, implying mix-driven unit gains despite lower ticket sizes. The pattern implies Homiez’s revenue engine is pivoting toward faster-turn, value-leaning formats where Concentrates’ velocity outpaced Pre-Roll on both YoY (530.22% vs 168.68%) and MoM (56.31% vs 36.61%), while Flower’s negative MoM (-25.28%) signals deprioritization and limited near-term contribution.

These shifts position Homiez as a dual-format player anchored in Pre-Roll scale (51.23% share, rank 36 in Michigan Pre-Roll) and accelerated by Concentrates growth (42.40% share, 56.31% MoM), suggesting the brand competes on accessibility via lower price points relative to category averages. The divergence—higher-priced Flower at 33.08 losing MoM share against lower-priced Concentrates at 7.17 and mid-priced Pre-Roll at 15.50—indicates a deliberate tilt toward price-elastic segments, implying further gains are more likely if the portfolio continues to emphasize Concentrates’ higher growth rate and protects Pre-Roll’s rank while accepting Flower as a niche, margin-managed role.